These observations support using HDAC inhibitors as an attractive anti-synovial sarcoma strategy, which provides an advantage of attacking the oncogenic driver SS18-SSX, rather than an individual cofactor or a selected downstream target. Here, HDAC9 is linked to synovial sarcoma.